ABT vs SENS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ABT is the larger of the two ($189.10B market cap): the incumbent the market prices for continued execution (18.39x forward earnings, beta 0.54). SENS is the smaller challenger ($610.17M), priced similarly on forward earnings (-6.14x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ABT vs SENS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricABTSENSWhat it tells you
Market cap$189.10B$610.17MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E18.39-6.14Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range54% of range73% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book3.718.14How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ABT and SENS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABT and SENS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABT and SENS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Abbott Laboratories (ABT) do?

Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Medical Devices, the largest segment at roughly $21.4 billion in 2025 revenue, includes the FreeStyle Libre family of continuous glucose monitors, structural heart products (Navitor, TriClip), electrophysiology systems (AVEIR leadless pacemaker, Volt pulsed field ablation, TactiFlex Duo), vascular devices, and heart-failure technologies (CardioMEMS). Diagnostics contributed roughly $8.9 billion in 2025 before the Exact Sciences deal, Nutrition roughly $8.5 billion (anchored by Similac infant formula and Ensure adult nutrition), and Established Pharmaceuticals roughly $5.5 billion in branded generics sold primarily in emerging markets.

Full ABT guide

What does Senseonics Holdings (SENS) do?

Senseonics Holdings develops and commercializes Eversense, a continuous glucose monitoring system for people with diabetes built around a small sensor implanted just under the skin of the upper arm. Unlike the disposable adhesive sensors from Dexcom and Abbott that last roughly 10 to 15 days, Eversense is designed for long-term wear, and the current Eversense 365 version is approved for up to one year on a single sensor, paired with a removable transmitter and a phone app. The long-wear, low-maintenance profile is the company's core differentiator in an otherwise patch-dominated category.

Full SENS guide

ABT vs SENS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ABT drivers: FreeStyle Libre: A Platform, Not Just a Product; Cardiovascular and Electrophysiology Momentum.
  • SENS drivers: Eversense 365 one-year differentiation; Bringing commercialization in-house from Ascensia.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. For SENS, senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence.

ABT or SENS: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABT if you believe its drivers more; SENS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABT and SENS guides.

ABT vs SENS: the full fundamentals

ABT. ABT's trailing GAAP P/E of about 34x is inflated by acquisition amortization and one-time costs from the Exact Sciences deal; on forward earnings the stock trades near 17x, well below its own 5-year and 10-year historical averages, after a roughly 16% decline in 2026. Revenue growth has remained positive, and the raised adjusted EPS guidance of $5.45-$5.60 implies a forward adjusted P/E of about 19x at the October 16 price of $104.44, below the average analyst target of about $121. Q3 2026 results are due October 21, with company guidance of $1.38-$1.46 adjusted EPS and consensus near $1.41 on about $13.0 billion of sales.

SENS. These figures describe a speculative growth company, not a mature one: revenue is rising quickly off a small base while net losses remain large relative to sales, and the market values it at roughly 9 times trailing revenue with no earnings to measure. Cash of about $143 million after the 2026 raise covers roughly one year of guided cash use, so further capital raises are possible. Third-quarter results are due November 4, 2026, with consensus at about $16.2 million of revenue and a loss of about $0.52 a share. All figures are approximate and tied to the asOf date; verify against the latest filings before acting.

Headline figures (approximate, October 2026): ABT shows revenue (ttm) ~$46.6 billion (Q2 2026 sales $12.59 billion, +13% reported, +4.8% comparable), revenue (fy 2025) ~$44.3 billion (+5.7% YoY), net income (ttm) ~$5.4 billion (GAAP EPS ~$3.10), net profit margin (ttm) ~11.7%; SENS shows revenue (ttm) ~$48.6M (FY2025 ~$35.3M), q2 2026 revenue ~$14.5M (up ~120% year over year), full-year 2026 revenue guidance ~$62M to $66M (raised in August 2026), gross margin 59% in Q2 2026; 2026 guidance 58-61%.

The bottom line: ABT vs SENS

ABT and SENS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABT and SENS exposure against your real portfolio. It is not an investment adviser.

Wondering how ABT or SENS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Abbott Laboratories

Ask Walnut's AI anything about ABT and see how it fits what you own.

FAQ

What is the difference between ABT and SENS?

+

Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160 countries through four segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Senseonics Holdings develops and commercializes Eversense, a continuous glucose monitoring system for people with diabetes built around a small sensor implanted just under the skin of the upper arm. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ABT or SENS the better stock?

+

Neither is universally better. ABT is the larger incumbent; SENS is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ABT or SENS?

+

On forward P/E (as of November 2026), ABT trades at 18.39x and SENS at -6.14x, so SENS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ABT and SENS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ABT vs SENS?

+

ABT: The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. Abbott has started to narrow this exposure, reaching agreements in August 2026 to resolve a portion of the preterm-formula litigation and an agreement with the Department of Justice in September 2026 on claims tied to the 2022 recall, but the remaining liability is still open-ended. Integration of the approximately $21 billion Exact Sciences acquisition introduces execution risk, amortization and elevated SGA costs: GAAP EPS was only $0.53 in Q2 2026 against adjusted EPS of $1.31, and the trailing GAAP P/E is about 34x even though the forward multiple is about 17x. Organic growth also slowed to 4.8% in Q2 2026 on a comparable basis, below the full-year 6.5-7.5% guide. Foreign exchange swings move reported international revenue by several percentage points, and any meaningful dollar strengthening would pressure reported results disproportionately given Abbott's broad non-US exposure. Competitive disruption in continuous glucose monitoring from DexCom and emerging players, along with pricing pressure from government payers and the Inflation Reduction Act, represent structural long-term headwinds. SENS: Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Scale is small, so a single reimbursement decision, manufacturing issue, or slower-than-expected patient adoption can move results materially. The company remains unprofitable and burns cash, so it has relied on equity and debt financing that can dilute shareholders. Reimbursement and regulatory outcomes across the U.S. and Europe add further uncertainty. The 2026 figures make the trade-off concrete: trailing revenue of about $49 million against a trailing net loss of about $109 million, guided 2026 cash use of $110-120 million against about $143 million of cash at mid-year, and international revenue that grew only about 12% in the second quarter. The stock is volatile in both directions, up about 63% over three months to mid-October 2026 but down about 15% in the final month.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABT or SENS; figures are approximate and dated (as of November 2026). Verify current data before investing.